Your Treatment Journey: From Crisis to Control
At a Glance
Birdshot chorioretinopathy treatment usually begins with corticosteroids to control active inflammation, followed by steroid-sparing immune therapy when needed. Regular eye tests, blood work, infection screening, and slow medication tapering help maintain remission.
Treating Birdshot Chorioretinopathy (BSCR) is a long-term commitment. Because the disease is chronic and the immune system remains “primed” to attack the eye, the goal of treatment is to reach and maintain remission—a state where there is no detectable inflammation [1].
The standard approach is a “step-ladder” strategy: starting with powerful medications to stop active damage and then transitioning to safer, long-term therapies to keep the disease quiet [2][3].
Phase 1: “Putting Out the Fire” (Corticosteroids)
When you are first diagnosed or having a flare, the immediate priority is to stop inflammation quickly. Doctors use corticosteroids (like prednisone) for this “induction” phase [2].
- How they work: Steroids are broad-acting anti-inflammatories that work almost immediately to reduce swelling and clear haziness [2].
- The Problem with Long-Term Use: While effective, taking high doses of steroids for a long time causes significant toxicity. This includes eye-specific risks like cataracts and glaucoma (high eye pressure), as well as systemic issues like weight gain, bone thinning (osteoporosis), and high blood sugar [4][5].
- The Goal: Doctors aim to “taper” (slowly reduce) your prednisone dose as safely as possible, often targeting a lower maintenance dose (such as 7.5 mg or less per day) or working to stop it completely over time [1]. This timeline varies widely by patient.
- Safety Warning: You must NEVER stop or rapidly taper corticosteroids on your own without a doctor’s plan, as this can trigger a dangerous adrenal crisis or a severe flare of your disease.
Phase 2: Steroid-Sparing Therapy (IMTs)
To allow you to stop or reduce steroids, specialists introduce Immunomodulatory Therapies (IMTs). These medications target the immune system more precisely [3].
- Common Options: The most frequently used IMTs for Birdshot include Mycophenolate Mofetil (CellCept), Methotrexate, and Cyclosporine or Tacrolimus [6][7].
- Timing: These drugs do not work instantly; they can take weeks or months to reach full effectiveness in your system [8].
- Monitoring: Because these medications affect the immune system and are processed by your internal organs, you will need regular blood tests (often every 1 to 3 months, or as directed) to check your Complete Blood Count (CBC), liver enzymes, and kidney function [9][10].
Phase 3: Biologic Therapies
In Birdshot, the choice among conventional IMT, local steroid approaches, and biologics is individualized. If conventional IMTs are not enough to control the disease, your doctor may move to biologic therapies [3].
- Anti-TNF Agents: Medications like Adalimumab (Humira) or Infliximab (Remicade) block a specific protein (TNF-alpha) that drives inflammation [11][12]. These drugs are often used off-label for this specific disease, and the evidence comes largely from observational studies rather than large trials.
- Effectiveness: In patients where other drugs failed, biologics have been shown to help suppress activity and reduce the need for oral steroids [11].
- Safety: Before starting a biologic, you must be screened for “hidden” infections like Tuberculosis (TB) or Hepatitis, as these drugs can cause those infections to reactivate [9][13].
The Long Road to Remission
In Birdshot, “feeling fine” is not the same as being in remission. Your doctor will use imaging (like FA and ICGA) and functional tests (like ERG) to confirm the disease is truly quiet [14][15].
- Sustained Remission: Many specialists aim to reach a state of “total quiet” for a prolonged period (such as 30 months or more) before considering a very slow taper of your main immunosuppressant [16].
- The Risk of Relapse: Birdshot is known for “late recurrences.” Even after years of quiet, the disease can flare up if medications are stopped too quickly [16]. One specialized study found that 78% of patients were successfully controlled at the five-year mark, but this success required consistent medication and monitoring [17].
Critical Medication Safety
| Drug Class | Key Monitoring & Cautions | Important Side Effects & Risks |
|---|---|---|
| Corticosteroids (Prednisone) | Blood pressure, Glucose, Bone density check | Weight gain, mood changes, cataracts. Do not stop abruptly [4]. |
| Antimetabolites (Mycophenolate, Methotrexate) | Liver enzymes, CBC. Strict contraception required. | Nausea, fatigue. Major fetal risks (birth defects) and pregnancy loss. Liver/lung toxicity (Methotrexate) [9]. |
| Calcineurin Inhibitors (Cyclosporine, Tacrolimus) | Kidney function, Blood pressure | Tremors, kidney stress, high blood pressure [18]. |
| Biologics (Adalimumab, Infliximab) | TB/Hepatitis screening, Infection signs | Injection site redness. Increased infection risk [19]. |
Infection Signs & Vaccines: Immunosuppressants lower your ability to fight infections. Call your doctor immediately if you develop a fever, chills, or persistent infection signs. Discuss all vaccinations with your doctor, as “live” vaccines are generally prohibited while on these therapies.
Common questions in this guide
What is the usual treatment plan for Birdshot chorioretinopathy?
Why are steroid-sparing medicines used for birdshot?
What monitoring is needed during Birdshot chorioretinopathy treatment?
Can I stop prednisone when my vision feels normal?
How do doctors know when Birdshot chorioretinopathy is in remission?
How long might treatment for Birdshot chorioretinopathy continue?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Birdshot chorioretinopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our target prednisone dose for the next three months, and at what point will we consider my inflammation 'controlled' enough to start a steroid-sparing medication?
- 2.Which specific conventional immunosuppressant (like mycophenolate or methotrexate) do you recommend for me, and how will we monitor its effect on my liver and kidneys?
- 3.If we see a decline in my ERG 'flicker' timing but my vision is still 20/20, will we consider that a sign to escalate treatment?
- 4.What are the specific 'success markers' we are looking for on my next FA and ICGA scans before we discuss tapering my medications?
- 5.Before I start a biologic like adalimumab, what screenings (such as TB or hepatitis) do I need to complete?
References
References (19)
- 1
Treatment Outcomes in Birdshot Chorioretinitis: Corticosteroid Sparing, Corticosteroid Discontinuation, Remission, and Relapse.
Crowell EL, France R, Majmudar P, et al.
Ophthalmology. Retina 2022; (6(7)):620-627 doi:10.1016/j.oret.2022.03.003.
PMID: 35283323 - 2
Efficacy of Methylprednisolone Pulse Followed by Oral Prednisone in Birdshot Chorioretinopathy.
Hafidi M, Loria O, Kodjikian L, et al.
Ocular immunology and inflammation 2017; (25(5)):596-603 doi:10.1080/09273948.2016.1178778.
PMID: 27380253 - 3
Prognostic Factors of Treatment Failure with First-Line Corticosteroid-Sparing Agents in Patients with Birdshot Chorioretinopathy: A Retrospective Study.
Goupillou P, Leclercq M, Muraine M, et al.
Ocular immunology and inflammation 2025; (33(7)):1298-1302 doi:10.1080/09273948.2025.2491570.
PMID: 40262577 - 4
Case Report: A Promising Treatment Strategy for Noninfectious Uveitis.
Liu XB, Tang LS, Chen JW, et al.
Frontiers in pharmacology 2021; (12()):784860 doi:10.3389/fphar.2021.784860.
PMID: 35115933 - 5
Uveitis in Adults: A Review.
Maghsoudlou P, Epps SJ, Guly CM, Dick AD
JAMA 2025; (334(5)):419-434 doi:10.1001/jama.2025.4358.
PMID: 40434762 - 6
Birdshot Chorioretinopathy with Cystoid Macular Oedema.
Valmaggia P, Loeliger J, Habra O
Klinische Monatsblatter fur Augenheilkunde 2026; (243(4)):457-460 doi:10.1055/a-2795-6069.
PMID: 41730283 - 7
Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review.
Calvo-Río V, Blanco R, Santos-Gómez M, et al.
Ocular immunology and inflammation 2017; (25(5)):604-609 doi:10.1080/09273948.2016.1231331.
PMID: 27726475 - 8
Pediatric uveitis: A comprehensive review.
Maleki A, Anesi SD, Look-Why S, et al.
Survey of ophthalmology 2022; (67(2)):510-529 doi:10.1016/j.survophthal.2021.06.006.
PMID: 34181974 - 9
Long-term safety of steroid-sparing immunosuppression in uveitis.
Placide J, Uner OE, Suhler EB
Current opinion in ophthalmology 2026; (37(6)):442-447 doi:10.1097/ICU.0000000000001242.
PMID: 42669172 - 10
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.
Dick AD, Rosenbaum JT, Al-Dhibi HA, et al.
Ophthalmology 2018; (125(5)):757-773 doi:10.1016/j.ophtha.2017.11.017.
PMID: 29310963 - 11
ADALIMUMAB THERAPY FOR REFRACTORY BIRDSHOT CHORIORETINOPATHY.
Huis Het Veld PI, van Asten F, Kuijpers RWAM, et al.
Retina (Philadelphia, Pa.) 2019; (39(11)):2189-2197 doi:10.1097/IAE.0000000000002281.
PMID: 30067605 - 12
Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy.
Steeples LR, Spry P, Lee RWJ, Carreño E
International ophthalmology 2018; (38(3)):1357-1362 doi:10.1007/s10792-017-0592-5.
PMID: 28608031 - 13
Noninfectious uveitis: Management with biologic agents.
Rathinam SR, Anjana S
Indian journal of ophthalmology 2026; (74(6)):837-844 doi:10.4103/IJO.IJO_3239_25.
PMID: 41817543 - 14
Evidence and Consensus-based Imaging Guidelines in Birdshot Chorioretinopathy: Multimodal Imaging in Uveitis (MUV) Taskforce Report 8.
Pichi F, Miserocchi E, Grewal DS, et al.
American journal of ophthalmology 2025; (278()):271-281 doi:10.1016/j.ajo.2025.06.029.
PMID: 40545009 - 15
Visual Electrodiagnostic Testing in Birdshot Chorioretinopathy.
Tzekov R, Madow B
Journal of ophthalmology 2015; (2015()):680215 doi:10.1155/2015/680215.
PMID: 26246903 - 16
Late recurrence in birdshot chorioretinopathy.
Maleki A, Look-Why S, Manhapra A, et al.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2023; (58(2)):77-81 doi:10.1016/j.jcjo.2021.08.006.
PMID: 34534507 - 17
Long-term outcomes of systemic corticosteroid-sparing immunomodulatory therapy for Birdshot Retinochoroidopathy.
You C, Lasave AF, Kubaisi B, et al.
Ocular immunology and inflammation 2020; (28(6)):966-974 doi:10.1080/09273948.2019.1641610.
PMID: 31567006 - 18
Efficacy of Tacrolimus in Uveitis, and the Usefulness of Serum Tacrolimus Levels in Predicting Disease Control. Results from a Single Large Center.
Luis J, Alsaedi A, Phatak S, et al.
Ocular immunology and inflammation 2022; (30(7-8)):1654-1658 doi:10.1080/09273948.2021.1930063.
PMID: 34124991 - 19
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies.
Xiong A, Liu D, Chen H, et al.
Frontiers in pharmacology 2021; (12()):620340 doi:10.3389/fphar.2021.620340.
PMID: 34603013
This page is for informational purposes only and does not constitute medical advice about Birdshot chorioretinopathy. Do not change or stop corticosteroids or immunosuppressive medicines without guidance from your ophthalmologist or treatment team.